サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1133515

放射性医薬品の世界市場-2022-2029

Global Radiopharmaceuticals Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
放射性医薬品の世界市場-2022-2029
出版日: 2022年10月11日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

放射性医薬品市場の成長は、がんや神経疾患などのさまざまな疾患の有病率の上昇、疾患の診断と治療における放射性医薬品の採用の増加、高齢者人口の増加、研究開発活動によってもたらされています。

放射性医薬品における製品開発の高まりが市場成長の原動力になると予想されます。

がんや心血管疾患などの疾病の有病率の上昇は、予測期間中に市場を押し上げると予想されます。国立がん研究所2020年10月データレポートによると、研究者は最近、肺がん、メラノーマ、大腸がん、白血病など多様ながんのために放射性医薬品を設計し、試験しています。また、Lutetium Lu 177などの標的分子を再利用して、より強力な放射性化合物や同位体を運ぶようにしました。例えば、前立腺がんは、この再利用のための初期の実験場となっています。PSMAは前立腺細胞に大量に存在し、そのほとんどが前立腺細胞にしか存在しないです。PSMAと結合する分子を放射性化合物と融合させることで、PETスキャンによる画像診断に利用されています。

さらに、放射性医薬品を他の治療法と組み合わせて使用することが、その改善を促進する一つの方法となるかもしれません。現在、一部の研究者は放射性医薬品と放射線増感剤（がん細胞が放射線に対してさらに脆弱になる薬物）の併用を試験しています。例えば、ルテチウムLu177ドタテートとトリアピンという放射線増感剤を併用した臨床試験では、放射線による損傷後のDNA修復に必要な化合物を細胞が産生するのを阻害します。

放射性医薬品治療のデメリットが市場成長の妨げになる

しかし、放射性医薬品治療のデメリットには、放射線のリスク、この治療法では通常、血流への注射が必要なため病気に特異的でない画像、放射能廃棄物の処理、治療費の高さなどがあります。これらの要因が、市場の成長を抑制しています。

COVID-19の影響分析

COVID-19の出現は、世界の放射性医薬品市場にかなりの影響を及ぼしました。コロナウイルス-19病（COVID-19）の大流行は、間違いなく世界のヘルスケアシステムに大きな課題を突きつけました。ファイザーの声明によると、COVID-19ががん患者に与える最大の影響の1つは、手術や臨床試験の中断による恐怖心です。また、英国がん研究会は2020年4月、英国全体で腸がん、乳がん、子宮頸がんの検診を受ける人がパンデミック前より毎週約20万人減少し、相当数の早期がんが診断されないと報告しています。また、放射線治療の治療コースも大幅に減少し、2019年の同じ月に比べて2020年4月は20％近く、5月は6.2％、6月は11.6％減少しています。

さらに、パンデミック時でも研究を進めている団体もあります。例えば、がん研究会（CRI）は、世界中の機関でがんの臨床試験を実施している36人の治験責任医師を対象にした調査結果を報告しています。2022年状況はCOVID-19から回復しており、患者は適切な治療にアクセスすることができ、世界中で放射性医薬品治療の市場成長につながります。

世界の放射性医薬品市場レポートでは、約65以上の市場データ表、65以上の図、200以上のページ（概算）の範囲でのアクセスを提供することになります。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場インパクトファクター
    • 促進要因
      • 癌や心血管疾患の高い有病率
      • 感染症対策需要の高まり
    • 抑制要因
      • 放射性医薬品の半減期の短さ
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • プライシング分析
  • アンメットニーズ分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 放射性同位元素別

  • テック99
  • F18
  • ヨウ素131
  • ルテチウム177
  • イットリウム90
  • ガリウム68
  • ガリウム67
  • ルビジウム82
  • ヨウ素123
  • ヨウ素125
  • インジウム111
  • その他

第8章 アプリケーション別

  • オンコロジー
  • 循環器領域
  • 消化器病学
  • 神経内分泌学
  • 神経内科領域
  • 神経内科
  • その他

第9章 ソース別

  • サイクロトロン
  • 原子炉

第10章 エンドユーザー別

  • 病院
  • 画像診断センター
  • 外来手術センター
  • がん研究機関

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 治療タイプ別ベンチマーク

第13章 企業プロファイル

  • Siemens AG
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Positron Corporation
  • Curium
  • GE Healthcare
  • Lantheus Holdings Inc.
  • Sotera Health LLC
  • Bayer AG
  • Eckert & Ziegler
  • Novartis AG
  • BWX Technologies Inc.

第14章 放射性医薬品の世界市場-DataM

目次
Product Code: DMPH562

Market Overview

Radiopharmaceuticals Market size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 6.2% over the forecast period 2022 to 2029.

Radiopharmaceuticals contain radioactive substances used to diagnose or treat diseases, including cancer or cardiology. These are used for the diagnosis of abscess and infection, blood vessel diseases, bone diseases, colorectal disease and others.

Market Dynamics

The radiopharmaceuticals market growth is driven by the rise in prevalence of different diseases such as cancer, and neurological disorders, rising adoption of radiopharmaceuticals for diagnosis and treatment of diseases, increase in the geriatric population, and research and development activities.

The rising product development in radiopharmaceutical is expected to drive the market growth

The rising prevalence of diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. According to the National Cancer Institute October 2020 data report, researchers have recently designed and tested radiopharmaceuticals for various cancers as diverse as lung, melanoma, colorectal, and leukemia. Also, researchers have repurposed, such as Lutetium Lu 177, targeting molecules to carry more potent radioactive compounds, or isotopes, instead ones that could kill cancer cells instead of simply helping visualize them. For instance, prostate cancer has been an early testing ground for this repurposing. PSMA is found in large amounts and almost exclusively on prostate cells. Fusing a molecule that binds PSMA to a radioactive compound is used in PET scan imaging.

Moreover, using radiopharmaceuticals in combination with other therapies may be one way to drive that improvement. Some researchers are now testing radiopharmaceuticals combined with radiation sensitizers-drugs that make cancer cells even more vulnerable to radiation. For example, a clinical trial of lutetium Lu 177-dotatate combined with a radiation sensitizer called triapine, blocks cells from producing the compounds needed for DNA repair after radiation-induced damage.

The disadvantages of radiopharmaceuticals therapy will hamper the growth of the market

However, the disadvantages of radiopharmaceutical therapy include radiation risks, images that are not usually disease-specific, in this therapy typically requiring injection into the bloodstream, disposal of radioactivity waste and high cost of the treatment. These factors are restraining the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global radiopharmaceuticals market. The coronavirus-19 disease (COVID-19) pandemic has undoubtedly posed significant challenges to healthcare systems globally. According to a statement by Pfizer, one of the greatest effects of COVID-19 on cancer patients is fear due to surgery and clinical trial disruptions. In addition, Cancer Research UK reported in April 2020 that a considerable number of early cancers would go undiagnosed, as there was a significant reduction in the number of people being screened for bowel, breast and cervical cancer across the UK, approximately 200,000 fewer per week than before the pandemic. There was also a significant decrease in radiotherapy treatment courses, nearly 20 % in April 2020, 6.2 % in May and 11.6 % in June, compared to the same months in 2019.

In addition, some organizations are conducting their studies even during a pandemic. For instance, the Cancer Research Institute (CRI) reported the results of a survey of 36 investigators conducting cancer clinical trials at institutions around the world. In 2022 situation is recovering from COVID-19, and the patient can access the proper treatments, leading to market growth of radiopharmaceutical therapy worldwide.

Segment Analysis

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The oncology segment is expected to boost the market throughout the forecast. The article was published in Future Oncology in June 2020; reported that, as per the WHO, worldwide cancer cases are predicted to increase around 60%, from 18.1 million in 2018 to 29.4 million by 2040. Also, as per the article published in Nature Reviews Drug Discovery in July 2020, several radiopharmaceutical therapy (RPT) agents are currently on the market, with many more in development. For instance, Bayer is developing Radium-223 chloride for Bone metastasis, Novartis is developing 177Lu-labelled DOTATATE for Neuroendocrine tumors, and Telix Pharma developing 211At-labelled aLAT-1a for Multiple myeloma. These include four B-particle and five α-particle emitters. Lead-212 decays to bismuth-212 and is used to deliver 212Bi, an α-emitter, without being constrained by its 1-hour half-life. Of the 30 RPT agents mentioned in the article, 13 deliver radionuclides that decay by α-particle emission. The interest in α-emitters reflects a potential growth area in RPT. The development of the RPT is increasing as the incidence and demand for treatment are rising, leading to the oncology segment growth in the market.

Geographical Analysis

North America region holds the largest market share of the global radiopharmaceuticals market

North America dominates the radiopharmaceutical market and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to rising cancer and another disease, advanced healthcare, launching new products and the presence of many key players. In July 2022, according to the Centers for Disease Control and Prevention, About 20.1 million adults age 20 and older have CAD (about 7.2%). With the rising incidence of disease, there is a demand for suitable treatment in the North American region.

In addition, the key players are adopting market strategies to expand their business. For instance, in November 2020, Canadian radiopharmaceuticals leading company Fusion Pharmaceuticals collaborated with Anglo-Swedish Pharma leader AstraZeneca to commercialize and develop next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Also, in July 2022, PETNET Solutions Inc., a Siemens Healthineers company and the leading manufacturer of radiopharmaceuticals for positron emission tomography (PET) imaging in the United States, opened a new radiopharmacy in Florida, United States.

Competitive Landscape

The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens AG, Positron Corporation, Curium, GE Healthcare, Lantheus Holdings Inc., Sotera Health LLC, Bayer AG, Eckert & Ziegler, Novartis AG, and BWX Technologies Inc. among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.

For instance,

  • In March 2021, Aktis Oncology, a biotechnology company developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancer cases, announced the completion of a series for solid tumors.

Novartis AG

Overview:

Novartis AG is a Swiss-American multinational pharmaceutical company founded in 1996 and headquartered in Switzerland. The company offers radiopharmaceutical products, including gallium Ga 68, for treating diseases such as cancer, cardiology, neurology and infectious & inflammatory diseases.

Product Portfolio:

PLUVICTO: The PLUVICTO brand name for lutetium Lu 177 vipivotide tetraxetan is used for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

The global radiopharmaceuticals market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. High prevalence of cancer and cardiovascular disease
      • 4.1.1.2. Rising demand for infection control measure
    • 4.1.2. Restraints:
      • 4.1.2.1. The short half-life of radiopharmaceuticals
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Radioisotopes

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes Segment
    • 7.1.2. Market Attractiveness Index, By Radioisotopes Segment
  • 7.2. Tec.99 *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. F18
  • 7.4. Iodine 131
  • 7.5. Lutetium 177
  • 7.6. Yttrium 90
  • 7.7. Gallium 68
  • 7.8. Gallium 67
  • 7.9. Rubidium 82
  • 7.10. Iodine 123
  • 7.11. Iodine 125
  • 7.12. Indium 111
  • 7.13. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Oncology *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Cardiology
  • 8.4. Gastroenterology
  • 8.5. Neuroendocrinology
  • 8.6. Neurology
  • 8.7. Nephrology
  • 8.8. Others

9. By Source

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 9.1.2. Market Attractiveness Index, By Source
  • 9.2. Cyclotrons *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nuclear Reactor

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Imaging Centers
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Cancer Research Institute

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Source
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. Siemens AG*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Positron Corporation
  • 13.3. Curium
  • 13.4. GE Healthcare
  • 13.5. Lantheus Holdings Inc.
  • 13.6. Sotera Health LLC
  • 13.7. Bayer AG
  • 13.8. Eckert & Ziegler
  • 13.9. Novartis AG
  • 13.10. BWX Technologies Inc.

LIST NOT EXHAUSTIVE

14. Global Radiopharmaceuticals market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us